Brucella abortusS19 and RB51 vaccine immunogenicity test: Evaluation of three mice (BALB/c, Swiss and CD-1?) and two challenge strains (544 and 2308)

• Published in: Vaccine Vol. 33; no. 4; p. 507
• Main Authors: Miranda, Karina Leite, Dorneles, Elaine Maria Seles, Pauletti, Rebeca Barbosa, Poester, Fernando Padilla, Lage, Andrey Pereira
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 15.01.2015
• Subjects: Animal vaccines; Bacteriology; Breeding of animals; Brucellosis; Spleen; Studies; Brazil
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2014.11.056

The aim of the present study was to evaluate the use of different mouse strains (BALB/c, Swiss and CD-1®) and different challenge strains (Brucella abortus544 and 2308) in the study ofB. abortusvaccine (S19 and RB51) immunogenicity test in the murine model. No significant difference inB. abortusvaccine potency assay was found with the use ofB. abortus544 orB. abortus2308 as challenge strain. Results of variance analysis showed an interaction between treatment and mouse strain; therefore these parameters could not be compared separately. When CD-1®groups were compared, those vaccinated showed significantly lower counts than non-vaccinated ones (P<0.05), independently of the vaccine received (S19 or RB51). Similar results were observed on BALB/c groups. However, in Swiss mouse groups, S19 was more protective than RB51 (P<0.05), which showed protection when compared to the non-vaccinated group (P<0.05). In summary, data from the present study showed that CD-1®, BALB/c and Swiss mice strains, as well as both challenge strains,B. abortusstrains 544 and 2308, can be used in immunogenicity tests of S19 and RB51 vaccines.